{"entity":{"id":"nct04233346","kind":"trial","name":"The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation","aka":[],"tldr":"A phase 2 trial of Ponatinib in chronic myeloid leukaemia and acute lymphoblastic leukaemia, run by Otsuka Beijing Research Institute, active and no longer recruiting.","summary":"The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation is a phase 2 interventional study registered as NCT04233346 by Otsuka Beijing Research Institute, with 93 participants enrolled, started 2020-07-09 and due to reach its primary completion in 2022-07-22. Interventions recorded: Ponatinib 30mg OD and Ponatinib 45mg OD.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04233346","url":"https://clinicaltrials.gov/study/NCT04233346"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cml","all-leukemia","cml-advanced-phase"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["ponatinib"],"companies":["otsuka"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04233346","phase":"2","setting":"A Phase II Multi-center, Randomized, Open-label Study of Ponatinib in Chinese Patients With Chronic Myeloid Leukemia Who Have Failed Prior TKIs or With T315I Mutation, or Ph+ALL Who Have Failed Prior TKIs or With T315I Mutation","sponsor":"Otsuka Beijing Research Institute","participation":[{"nct":"NCT04233346","source":"https://clinicaltrials.gov/study/NCT04233346","fetchedAt":"2026-10-07T16:53:16.796Z","studySha256":"c7117ed79a839aed94fda347e39298a65b6125eee6f5d0f4695e3c8e4882f4ba","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2025-04-04","leadSponsor":"Otsuka Beijing Research Institute","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":93,"enrolmentType":"ACTUAL","siteCount":14,"recruitingSiteCount":0,"countries":["China"]}],"started":"2020-07-09","startedType":"actual","enrolled":93,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04233346/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/"},{"id":"cml-advanced-phase","kind":"cancer","name":"Chronic myeloid leukaemia, accelerated and blast phase","route":"/cancers/cml-advanced-phase/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"ponatinib","kind":"drug","name":"Ponatinib","route":"/drugs/ponatinib/"}],"company":[{"id":"otsuka","kind":"company","name":"Otsuka Pharmaceutical","route":"/companies/otsuka/"}]}}